175 related articles for article (PubMed ID: 9120016)
1. Pharmacological targeting of long QT mutant sodium channels.
Wang DW; Yazawa K; Makita N; George AL; Bennett PB
J Clin Invest; 1997 Apr; 99(7):1714-20. PubMed ID: 9120016
[TBL] [Abstract][Full Text] [Related]
2. Selective block of late currents in the DeltaKPQ Na(+) channel mutant by pilsicainide and lidocaine with distinct mechanisms.
Ono K; Kaku T; Makita N; Kitabatake A; Arita M
Mol Pharmacol; 2000 Feb; 57(2):392-400. PubMed ID: 10648650
[TBL] [Abstract][Full Text] [Related]
3. Molecular basis of ranolazine block of LQT-3 mutant sodium channels: evidence for site of action.
Fredj S; Sampson KJ; Liu H; Kass RS
Br J Pharmacol; 2006 May; 148(1):16-24. PubMed ID: 16520744
[TBL] [Abstract][Full Text] [Related]
4. Effects of sodium channel block with mexiletine to reverse action potential prolongation in in vitro models of the long term QT syndrome.
Sicouri S; Antzelevitch D; Heilmann C; Antzelevitch C
J Cardiovasc Electrophysiol; 1997 Nov; 8(11):1280-90. PubMed ID: 9395171
[TBL] [Abstract][Full Text] [Related]
5. A revised view of cardiac sodium channel "blockade" in the long-QT syndrome.
Kambouris NG; Nuss HB; Johns DC; Marbán E; Tomaselli GF; Balser JR
J Clin Invest; 2000 Apr; 105(8):1133-40. PubMed ID: 10772658
[TBL] [Abstract][Full Text] [Related]
6. Malignant perinatal variant of long-QT syndrome caused by a profoundly dysfunctional cardiac sodium channel.
Wang DW; Crotti L; Shimizu W; Pedrazzini M; Cantu F; De Filippo P; Kishiki K; Miyazaki A; Ikeda T; Schwartz PJ; George AL
Circ Arrhythm Electrophysiol; 2008 Dec; 1(5):370-8. PubMed ID: 19808432
[TBL] [Abstract][Full Text] [Related]
7. A molecular basis for the therapy of the long QT syndrome.
Priori SG; Napolitano C; Schwartz PJ
Arch Mal Coeur Vaiss; 1996 Sep; 89(9):1185-7. PubMed ID: 8952843
[TBL] [Abstract][Full Text] [Related]
8. Mexiletine rescues a mixed biophysical phenotype of the cardiac sodium channel arising from the SCN5A mutation, N406K, found in LQT3 patients.
Hu RM; Tester DJ; Li R; Sun T; Peterson BZ; Ackerman MJ; Makielski JC; Tan BH
Channels (Austin); 2018; 12(1):176-186. PubMed ID: 29983085
[TBL] [Abstract][Full Text] [Related]
9. Long QT syndrome patients with mutations of the SCN5A and HERG genes have differential responses to Na+ channel blockade and to increases in heart rate. Implications for gene-specific therapy.
Schwartz PJ; Priori SG; Locati EH; Napolitano C; Cantù F; Towbin JA; Keating MT; Hammoude H; Brown AM; Chen LS; Colatsky TJ
Circulation; 1995 Dec; 92(12):3381-6. PubMed ID: 8521555
[TBL] [Abstract][Full Text] [Related]
10. A distinct molecular mechanism by which phenytoin rescues a novel long QT 3 variant.
Gando I; Campana C; Tan RB; Cecchin F; Sobie EA; Coetzee WA
J Mol Cell Cardiol; 2020 Jul; 144():1-11. PubMed ID: 32339567
[TBL] [Abstract][Full Text] [Related]
11. Complex interactions in a novel SCN5A compound mutation associated with long QT and Brugada syndrome: Implications for Na+ channel blocking pharmacotherapy for de novo conduction disease.
Liu J; Bayer JD; Aschar-Sobbi R; Wauchop M; Spears D; Gollob M; Vigmond EJ; Tsushima R; Backx PH; Chauhan VS
PLoS One; 2018; 13(5):e0197273. PubMed ID: 29791480
[TBL] [Abstract][Full Text] [Related]
12. Mexiletine block of wild-type and inactivation-deficient human skeletal muscle hNav1.4 Na+ channels.
Wang GK; Russell C; Wang SY
J Physiol; 2004 Feb; 554(Pt 3):621-33. PubMed ID: 14608007
[TBL] [Abstract][Full Text] [Related]
13. Trafficking defects and gating abnormalities of a novel SCN5A mutation question gene-specific therapy in long QT syndrome type 3.
Ruan Y; Denegri M; Liu N; Bachetti T; Seregni M; Morotti S; Severi S; Napolitano C; Priori SG
Circ Res; 2010 Apr; 106(8):1374-83. PubMed ID: 20339117
[TBL] [Abstract][Full Text] [Related]
14. Preferential block of late sodium current in the LQT3 DeltaKPQ mutant by the class I(C) antiarrhythmic flecainide.
Nagatomo T; January CT; Makielski JC
Mol Pharmacol; 2000 Jan; 57(1):101-7. PubMed ID: 10617684
[TBL] [Abstract][Full Text] [Related]
15. Gating properties of SCN5A mutations and the response to mexiletine in long-QT syndrome type 3 patients.
Ruan Y; Liu N; Bloise R; Napolitano C; Priori SG
Circulation; 2007 Sep; 116(10):1137-44. PubMed ID: 17698727
[TBL] [Abstract][Full Text] [Related]
16. Characterization of human cardiac Na+ channel mutations in the congenital long QT syndrome.
Wang DW; Yazawa K; George AL; Bennett PB
Proc Natl Acad Sci U S A; 1996 Nov; 93(23):13200-5. PubMed ID: 8917568
[TBL] [Abstract][Full Text] [Related]
17. Molecular pharmacology of the sodium channel mutation D1790G linked to the long-QT syndrome.
Abriel H; Wehrens XH; Benhorin J; Kerem B; Kass RS
Circulation; 2000 Aug; 102(8):921-5. PubMed ID: 10952963
[TBL] [Abstract][Full Text] [Related]
18. [Molecular genetics in the hereditary form of long QT syndrome].
Georgijević Milić L
Med Pregl; 2000; 53(1-2):51-4. PubMed ID: 10953551
[TBL] [Abstract][Full Text] [Related]
19. Predicting Patient Response to the Antiarrhythmic Mexiletine Based on Genetic Variation.
Zhu W; Mazzanti A; Voelker TL; Hou P; Moreno JD; Angsutararux P; Naegle KM; Priori SG; Silva JR
Circ Res; 2019 Feb; 124(4):539-552. PubMed ID: 30566038
[TBL] [Abstract][Full Text] [Related]
20. A trafficking defective, Brugada syndrome-causing SCN5A mutation rescued by drugs.
Valdivia CR; Tester DJ; Rok BA; Porter CB; Munger TM; Jahangir A; Makielski JC; Ackerman MJ
Cardiovasc Res; 2004 Apr; 62(1):53-62. PubMed ID: 15023552
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]